ViatrisVTRS
About: Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Employees: 38,000
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
19% more first-time investments, than exits
New positions opened: 86 | Existing positions closed: 72
16% more call options, than puts
Call options by funds: $39M | Put options by funds: $33.8M
9% more funds holding in top 10
Funds holding in top 10: 11 [Q2] → 12 (+1) [Q3]
4% more capital invested
Capital invested by funds: $10.6B [Q2] → $11B (+$402M) [Q3]
0% less funds holding
Funds holding: 980 [Q2] → 979 (-1) [Q3]
2% less repeat investments, than reductions
Existing positions increased: 344 | Existing positions reduced: 351
4.35% less ownership
Funds ownership: 83.89% [Q2] → 79.54% (-4.35%) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Piper Sandler David Amsellem 58% 1-year accuracy 23 / 40 met price target | 24%upside $14 | Neutral Reiterated | 6 Dec 2024 |
Barclays Balaji Prasad 47% 1-year accuracy 21 / 45 met price target | 6%upside $12 | Underweight Maintained | 8 Nov 2024 |
Financial journalist opinion
Based on 5 articles about VTRS published over the past 30 days
